An individual may be the presenting author on one podium presentation at AAIC.
Podium presentations include featured research, oral, symposium and plenary sessions.
Podium presentation in a preconference does not count towards AAIC.
Exception: An individual may only present in two AAIC podium platforms if one is a
Developing Topic session (i.e. late breaking abstracts collected in the spring)."
squal...are you certain? Can you provide any AAIC doc/text that says it is 1 hr developing topic presentation? It should one or the other??
Gamble if you want but if this news is as expected AVXL will never look back. My guess is some kind of minor drop is possible after AAIC but, depending on data, that may not happen.
I think you are correct but would feel a little better if we see an AAIC PR on late breaking presentation by Dr M, in addition to posters already set. My thought is that news is leaking.
This is what happened in 2015 on June 30:(PR)-no certainty they will repeat of course
NEW YORK, NY – June 30, 2015 – Anavex Life Sciences Corp. (“Anavex” or the “Company”) (OTCQX: AVXL) a clinical-stage biopharmaceutical company developing drug candidates to treat Alzheimer’s disease, other central nervous system (CNS) diseases, pain, and various types of cancer, today announced the presentation of initial clinical data from the ongoing Phase 2a clinical trial of ANAVEX 2-73 during the upcoming Alzheimer’s Association International Conference® 2015 (AAIC), which takes place in Washington D.C. from July 18-23, 2015.
Walk off HR..priceless...Red Sox beat Yankees in world series while the best team money can buy (BP)hits the showers....it does not get any better.
Try this. The deadline for abstract submission was in Feb 2016. The A2-73 trial data was not available then. Two poster presentations now planned by Dr M. Note the topics being A2-73 related and current(no restrictions on time there). Next, if the AAIC council judges that late breaking A2-73 results warrant a spot(see criteria) on the podium then it further validates the significance of results. Any PR/announcement on "late breaking" is expected over the next couple of days. This is a similar pattern to last years AAIC w/A2-73.
Developing Topic submissions are designed to bring the latest research findings in the field to AAIC attendees. Specifically, Developing Topic abstracts present research findings that were not available at the time of the general abstract submission deadline in February.
Note: AAIC 2016 Developing Topic abstracts will be considered for poster presentation only unless the research is considered to be late-breaking.
Late-breaking research/newness of information.
Potential impact on the research community.
Quality of scientific research.
Relevance to Alzheimer's disease and related disorders.
Topics of interest include basic and translational science, diagnosis and prognosis, therapeutics, and public health and psychosocial issues.
Previously submitted/reviewed abstracts will not be considered.
A limited number of abstracts are selected, with selection based on timeliness and scientific merit.
Only under extraordinary circumstances will abstracts without results be considered.
Accepted abstracts are published in an online supplement to the Association's journal, Alzheimer's & Dementia: The Journal of the Alzheimer's Association.
Developing Topic abstracts must be submitted via the online system.
Developing Topic abstracts are not accepted for the Alzheimer's Imaging Consortium or Technology and Dementia.
Developing Topic abstracts do not include the AAIC Featured Research Session format.
An individual may be the presenting author on one oral presentation (includes a featured research session) and two posters slotted on different days. Exception: An author may present in two oral platforms as long as one is a Developing Topic session.